Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
24.75
+0.60 (2.48%)
At close: Nov 25, 2025, 4:00 PM EST
24.80
+0.05 (0.20%)
Pre-market: Nov 26, 2025, 5:53 AM EST
Moderna Stock Forecast
Stock Price Forecast
The 11 analysts that cover Moderna stock have a consensus rating of "Hold" and an average price target of $33.91, which forecasts a 37.01% increase in the stock price over the next year. The lowest target is $18 and the highest is $63.
Price Target: $33.91 (+37.01%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Moderna stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 13 | 13 | 12 | 12 | 8 | 8 |
| Sell | 3 | 3 | 4 | 4 | 4 | 3 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 15 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $69 → $63 | Buy | Reiterates | $69 → $63 | +154.55% | Nov 21, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $28 → $25 | Hold | Maintains | $28 → $25 | +1.01% | Nov 21, 2025 |
| Leerink Partners | Leerink Partners | Sell Maintains $15 → $18 | Sell | Maintains | $15 → $18 | -27.27% | Nov 21, 2025 |
| Barclays | Barclays | Hold Maintains $31 → $25 | Hold | Maintains | $31 → $25 | +1.01% | Nov 7, 2025 |
| UBS | UBS | Strong Buy Maintains $70 → $40 | Strong Buy | Maintains | $70 → $40 | +61.62% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
1.94B
from 3.24B
Decreased by -40.14%
Revenue Next Year
2.14B
from 1.94B
Increased by 10.38%
EPS This Year
-9.96
from -9.28
EPS Next Year
-7.91
from -9.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.3B | 3.2B | |||
| Avg | 1.9B | 2.1B | |||
| Low | 1.5B | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -28.8% | 63.5% | |||
| Avg | -40.1% | 10.4% | |||
| Low | -53.3% | -32.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -8.86 | -6.00 | |||
| Avg | -9.96 | -7.91 | |||
| Low | -10.50 | -9.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.